Treatment of Congenital Hemophilia A and B
Publication Date: June 19, 2024
Key Points
Key Points
- Hemophilia is a congenital X-linked bleeding disorder that affects an estimated 1,125,000 individuals worldwide, 80% of whom have hemophilia A.
- Individuals with severe (and some moderate) forms of hemophilia not treated with prophylaxis may experience spontaneous bleeding, of which the most frequent are joint and muscle bleeding.
- Prophylaxis rather than episodic treatment is strongly recommended for severe and moderately-severe hemophilia A and B.
Treatment
...eatment
...a A Without Inhibitors...
...with severe and moderately-severe hemophili...
...dividuals with severe and moderately-severe hemop...
...with severe and moderately-severe he...
...limited settings in which the use...
...treated individuals with severe hemop...
...iduals with severe and moderately-se...
...hilia A With Inhibitors...
...ls with severe hemophilia A with inhibito...
...with severe hemophilia A with inh...
...ndividuals with severe hemophilia A with high-resp...
...individuals with severe hemophilia A wi...
...dividuals with severe hemophilia A with inhibito...
Hemophilia B Without I...
...ls with severe and moderately-severe...
In individuals with severe and moderately-sev...